2014 News Releases

Webcast ImageWebcast
Neuralstem, Inc at BIO CEO & Investor Conference (Replay)
02/13/17 at 8:30 a.m. ET
Webcast ImageWebcast
Neuralstem, Inc. at 29th Annual ROTH Conference (Replay)
03/13/17 at 12:00 p.m. PT
Webcast ImageWebcast
Neuralstem, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/21/17 at 1:00 p.m. ET
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/17/14Neuralstem NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit
Depression Biomarker Analysis Shows NSI-189 is Rapidly and Persistently EfficaciousGERMANTOWN, Md., Nov. 17, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that blood-based biomarkers for major depressive disorder (MDD) identified a rapid response to NSI-189 in  the Phase Ib MDD trial.   In the poster "Biomarker Profiling of NSI-189 Phosphate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD) during a Phase Ib Randomized Double-Blind, Pl... 
Download PDFPrinter Friendly Version
11/10/14Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology"
Study Concludes NSI-566 Cells Survived for up to 2.5 Years After Transplantation GERMANTOWN, Md., Nov. 10, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced the publication of results evaluating long term cell survival and differentiation of NSI-566 transplanted human spinal-cord derived neural stem cells (HSSC) in  Annals of Clinical and Translational Neurology (access now available). The study concluded that Neuralstem's investigational Phase I NSI-566 HSSCs survived for up... 
Download PDFPrinter Friendly Version
11/07/14Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
GERMANTOWN, Md., Nov. 7, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and nine months ended September 30, 2014 and provided a business and clinical update. "The third quarter of 2014 marked several important clinical milestones for Neuralstem," said Dr. Karl Johe, Chairman and CSO. "Using our lead NSI-566 cell therapy, we completed transplantation of the final cohort in our Phase II ALS trial and the first patient in our P... 
Download PDFPrinter Friendly Version
10/23/14Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting
GERMANTOWN, Md., Oct. 23, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first data in a study transplanting its neural stem cells in an animal model of Alzheimer's disease was presented at the Congress of Neurological Surgeons Annual Meeting, yesterday, in Boston, MA. In a late-breaking science oral presentation titled, "Peri-hippocampal stem cell transplantation rescues cognitive decline in Alzheimer's disease," Osama N. Kashlan, MD, of the departments of Neurology an... 
Download PDFPrinter Friendly Version
10/09/14First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center
NSI-566 to be Tested in Four Patients with Chronic Spinal Cord Injury GERMANTOWN, Md., Oct. 9, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated last week in the Phase I trial testing NSI-566 human neural stem cells in the treatment of chronic spinal cord injury (cSCI) at the UC San Diego School of Medicine. The patient has been discharged from the hospital. The NSI-566/cSCI Phase I trial will treat four patients who have thoracic spinal cor... 
Download PDFPrinter Friendly Version
09/22/14Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data
Some Patients Continue to Show Slowed Disease Progression or Improvement Three Years Post-Transplant GERMANTOWN, Md., Sept. 22, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up data on the Phase I trial testing NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).  The presentation, which occurred at the Annual ... 
Download PDFPrinter Friendly Version
09/05/14Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference
Live Webcast on Wednesday, September 10, at 2:55 p.m. EST GERMANTOWN, Md., Sept. 5, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 10, at 2:55 p.m. EST. Garr will provide an overview of the company's NSI-566 cell therapy clinical trials for ALS, which concluded final Phase II treatments in July, and chronic spinal cord injury,... 
Download PDFPrinter Friendly Version
08/08/14Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
GERMANTOWN, Md., Aug. 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a business and clinical update. "We are pleased to report that 2014 has already seen the company achieve several major milestones. In late July, we completed the last of the surgeries in the NSI-566/ALS Phase II trial. Each of the patients in the final cohort have received a total of 16 million NSI-566 neura... 
Download PDFPrinter Friendly Version
08/04/14Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial
GERMANTOWN, Md., Aug. 4, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The multicenter Phase II trial treated 15 ambulatory patients in five different dosing cohorts. The first 12 patients received injections in the cervical region of the spinal cord only, where the stem cells could hel... 
Download PDFPrinter Friendly Version
06/30/14Neuralstem Added To Russell 3000 Index
GERMANTOWN, Md., June 30, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000® Index. Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well a... 
Download PDFPrinter Friendly Version
06/25/14Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder
Cognitive Deficit and Depression Symptoms Improve Significantly, Trial Data Shows GERMANTOWN, Md., June 25, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, on June 17th, and the International College of Neuropyschopharmacology (CINP) Annual Meeting, on June 24th, 20... 
Download PDFPrinter Friendly Version
06/19/14Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress
GERMANTOWN, Md., June 19, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that select data from the NSI-189 Phase Ib trial in patients with major depressive disorder (MDD) will be presented at the International College of Neuropyschopharmacology (CINP) 2014  World Congress, in Vancouver, Canada. A poster entitled, "Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography  (qEEG) in patients with major depressive disorder (MDD) during a phas... 
Download PDFPrinter Friendly Version
06/18/14Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting
GERMANTOWN, Md., June 18, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR)  announced that final data from the Neuralstem NSI-189 Phase Ib study in major depressive disorder (MDD) was presented yesterday at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound, shown to promote neurogenesis in vitro. In animal studies, NSI-189 resulted in a 20% increase in hippocampa... 
Download PDFPrinter Friendly Version
05/23/14Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting
GERMANTOWN, Md., May 23, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that data from the NSI-189 Phase Ib study in major depressive disorder (MDD) will be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida, on June 17th at 4:15 EDT. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound. In pre-clinical studies, NSI-189 was shown to promote the formation of new neurons (neurogenesis) in animals an... 
Download PDFPrinter Friendly Version
05/16/14Neuralstem CEO, Richard Garr, to Present at World Stem Cells & Regenerative Medicine Congress and Give Update on Trials
/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK (http://www.terrapinn.com/conference/stem-cells/index.stm). Neuralstem is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord injury wi... 
Download PDFPrinter Friendly Version
05/12/14Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
ROCKVILLE, Md., May 12, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2014 and provided a business and clinical update. "During the first quarter of 2014, we continued to advance the NSI-566 cell therapy platform through human clinical trials. We have completed treatment of the fourth cohort in our ALS Phase II escalating dose trials, in collaboration with our sites at University of Michigan, Emory and Massac... 
Download PDFPrinter Friendly Version
05/08/14Neuralstem Appoints Sandford Drexel Smith, Former Genzyme Executive Vice President, To Board Of Directors
ROCKVILLE, Md., May 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Sandford Drexel Smith to its Board of Directors, bringing the total number of board members to seven, five of whom are independent. Mr. Smith is the former President, International Group, and Executive Vice President of Genzyme Corporation. He also served on Genzyme's Executive Committee, where he reported directly to the Chairman and CEO. As President of the International Group, Mr. Sm... 
Download PDFPrinter Friendly Version
04/16/14Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego
NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury ROCKVILLE, Md., April 16, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I safety trial to treat chronic spinal cord injury (cSCI) with its NSI-566 stem cells. The NSI-566/cSCI Phase I trial will enroll patients with thoracic spinal cord injuries (T2-T12) who have an American Spinal Injury Asso... 
Download PDFPrinter Friendly Version
04/07/14Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference
Will Also Present Update on Ongoing Phase II TrialROCKVILLE, Md., April 7, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, PhD, MD, principal investigator of Neuralstem's NSI-566 stem cell trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) will present Phase I data at the Keystone Symposia, "Engineering Cell Fate and Function," in Olympic Valley, California, on April 9th https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&... 
Download PDFPrinter Friendly Version
03/28/14Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats
ROCKVILLE, Md., March 28, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements. Furthermore, the grafts both survived and differentiated into neurons. These findings further validate the application of the cells for transplantation therapy in ischemic stroke.  The researchers conclud... 
Download PDFPrinter Friendly Version
03/17/14Final Results of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology
ROCKVILLE, Md., March 17, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology" http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full.  In "Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcom... 
Download PDFPrinter Friendly Version
03/10/14Neuralstem Announces 2013 Financial Results
ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)  "2013 was an exciting year for advancement in our NSI-566 cell therapy clinical programs," said Karl Johe, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "Our Phase II ALS trial commenced i... 
Download PDFPrinter Friendly Version
02/06/14Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014
Live Webcast to Air on Tuesday, February 11, at 3:00 p.m. EST ROCKVILLE, Md., Feb. 6, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual BIO CEO & Investor Conference 2014 in New York City on Tuesday, February 11, at 3:00 p.m. EST. Garr will present clinical updates on the company's 2014 NSI-566 cell therapy trials program, including ongoing ALS Phase II; ALS Phase II in Mexico City; FDA-appro... 
Download PDFPrinter Friendly Version
01/14/14Neuralstem Appoints Catherine Angell Sohn To Board Of Directors
ROCKVILLE, Md., Jan. 14, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors, bringing the total number of board members to six. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline, where she spearheaded global commercialization for this $8 billion division and led a series of international licensing de... 
Download PDFPrinter Friendly Version
01/13/14Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase
Updates on NSI-566 ALS Phase II - cSCI Phase I - Stroke Phase I/II, and NSI-189/MDD Live Audio Webcast to Air on Tuesday, January 14, at 3:30 p.m. PT ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the sixth annual Biotech Showcase (http://www.ebdgroup.com/bts/index.php) in San Francisco on Tuesday, January 14, 3:30 p.m. PT, in Room Powell (Track D). Garr will present a business overview, incl... 
Download PDFPrinter Friendly Version
01/13/14First Patient Treated In Neuralstem China Stem Cell Trial To Treat Stroke Motor Deficits
ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The trial is sponsored by Neuralstem's wholly-owned subsidiary, Neuralstem China (Suzhou Sun-Now Biopharmaceutical Co. Ltd.), which was formed to develop Neuralstem's c... 
Download PDFPrinter Friendly Version
01/09/14Neuralstem Closes $20 Million Registered Direct Offering
ROCKVILLE, Md., Jan. 9, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that on January 8, 2014, it closed on a $20 million investment from leading institutional and accredited investors in a registered direct placement (the "Offering") of 6,872,859 shares of common stock at a price of $2.91 per share. In addition, the Company issued to the investors in the Offering warrants to purchase common stock equal to one-half of the number of shares purchased by the invest... 
Download PDFPrinter Friendly Version
01/03/14Neuralstem To Raise $19.65 Million In Registered Direct Offering
ROCKVILLE, Md., Jan. 3, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it has entered into agreements with leading institutional investors for a registered direct placement (the "Offering") of 6,752,744 shares of common stock at a price of $2.91 per share, resulting in aggregate gross proceeds of approximately $19.65 million. In addition, the Company will issue to each investor a warrant to purchase a number of shares of common stock equal to one-half of th... 
Download PDFPrinter Friendly Version